Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220694 | 0.93 | OPRD1 (0.50) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL29610294 | 0.88 | OPRM1 (0.54) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL2183031 | 0.87 | OPRM1 (0.51) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL30393693 | 0.87 | OPRD1 (0.54) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL6497247 | 0.86 | F2 (0.57) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL2119635 | 0.86 | F2 (0.57) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL2778544 | 0.86 | F2 (0.57) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL6850160 | 0.86 | F2 (0.57) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL2778546 | 0.86 | F2 (0.57) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL6852479 | 0.86 | NMUR2 (0.54) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRD1 3100/4885OPRM1 2317/4885OPRK1 2737/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRD1 3100/4885OPRM1 2317/4885OPRK1 2737/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | OPRD1 2871/4885OPRM1 1535/4885OPRK1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.